Cord blood in regenerative medicine: do we need immune suppression? by Riordan, Neil H et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Review
Cord blood in regenerative medicine: do we need immune 
suppression?
Neil H Riordan1, Kyle Chan2, Annette M Marleau1 and Thomas E Ichim*1
Address: 1Medistem Laboratories Inc, Tempe Arizona, USA and 2Institute for Molecular Medicine, Huntington Beach, California, USA
Email: Neil H Riordan - nhriordan@gmail.com; Kyle Chan - kylechan@pacbell.net; Annette M Marleau - Annette.marleau@gmail.com; 
T h o m a sEI c h i m *-t h o m a s . i c h i m @ g m a i l . c o m
* Corresponding author    
Abstract
Cord blood is currently used as an alternative to bone marrow as a source of stem cells for
hematopoietic reconstitution after ablation. It is also under intense preclinical investigation for a
variety of indications ranging from stroke, to limb ischemia, to myocardial regeneration. A major
drawback in the current use of cord blood is that substantial morbidity and mortality are associated
with pre-transplant ablation of the recipient hematopoietic system. Here we raise the possibility
that due to unique immunological properties of both the stem cell and non-stem cell components
of cord blood, it may be possible to utilize allogeneic cells for regenerative applications without
needing to fully compromise the recipient immune system. Issues raised will include: graft versus
host potential, the immunogeneicity of the cord blood graft, and the parallels between cord blood
transplantation and fetal to maternal trafficking. The previous use of unmatched cord blood in
absence of any immune ablation, as well as potential steps for widespread clinical implementation
of allogeneic cord blood grafts will also be discussed.
Background
The first widespread utilization of cord blood as a stem
cell source was in the treatment of pediatric hematological
malignancies after myeloablative conditioning. Since
matching requirements for this type of transplant are not
as strict as for hematopoietic stem cell sources, cord blood
began gaining acceptance in adult patients lacking bone
marrow donors [1-6]. Outside the area of oncology, the
clinical use of cord blood has expanded into various areas
that range from reconstituting a defective immune system
[7], to correcting congenital hematological abnormalities
[8], to inducing angiogenesis [9]. A sample of some of
cord blood clinical studies addressing non-malignant dis-
orders is presented in Table 1.
In addition to current clinical use, cord blood is currently
under intense experimental investigation in preclinical
models of pathophysiologies that range from myocardial
ischemia, to stroke, to muscle regeneration [10-13]. It is
anticipated that in the next several years that widespread
clinical entry of cord blood for non-hematopoietic tissue
regeneration will occur. When this happens, the main
question will be how to select patients that can be myelo-
ablated so as to allow acceptance of the cord blood graft.
According to current dogma in the discipline, it is believed
that myeloablation, or at minimum non-ablative
immune suppression of the recipient is strictly required.
In situations of hematological malignancy it is desirable
to myeloablate the recipient so as to eradicate the leuke-
mic population while creating "space" for the donor cells
to engraft. However, the question is, in patients that are
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not suffering from a disease that is associated with an
aberrant bone marrow such as hematological malignan-
cies or immunological dysfunctions, how is it justifiable
to subject them to the high levels of morbidity and mor-
tality associated with immune suppression? For condi-
tions such as Krabbe disease where patients rarely survive
beyond the age of 2 and cord blood transplant was dem-
onstrated to induce 100% survival in a subgroup of
patients treated [14], the justification for myeloablation
can be made. However for conditions such as post-stroke
regeneration or induction of angiogenesis in angina
patients, in which the population already suffers from
major comorbidities and the potential benefit of cord
blood therapy is only speculative, the ability to justify
myeloablative protocols rapidly diminishes.
The purpose of this paper is to put forth the notion that
the immunology of cord blood transplants for regenera-
tive applications has to be viewed differently from the per-
spective and the practice of cord blood transplants for
hematopoietic reconstitution. Specifically, we will pro-
vide reasons and rational for why in some situations,
administration of cord blood, or stem cells derived
thereof, may be possible with no, or minimal immune
suppression of the recipient. Evaluation of this possibility
will lead to acceleration of clinical entry and wide-spread
utilization of cord blood transplants for non-hematopoi-
etic indications.
Regenerative cells in cord blood
Numerous publications have described the regenerative
ability of cord blood cells in a myriad of preclinical dis-
ease models. Although the purpose of this paper is to dis-
cuss the immunology of cord blood transplants for
regenerative uses, we will first overview some of the ther-
apeutic stem cell populations found in cord blood so that
we may discuss their immunogenic consequences later in
the paper.
Hematopoietic stem cells
The original clinically attractive feature of cord blood was
the high concentration of hematopoietic stem cells, which
is similar to that found in bone marrow: approximately
0.1–0.8 CD34+ cells per 100 nucleated cells. However, in
contrast to marrow, CD34+ cells from cord blood possess
higher proliferative potential in vitro [15], superior num-
bers of long term culture initiating cells and SCID repop-
ulating cells [16,17], as well as higher telomerase activity
[18]. The potent hematopoietic activity of cord blood
derived CD34+ cells may be attributed to the fact that cord
blood is a much more developmentally immature source
of stem cells as opposed to stem cells derived from adult
Table 1: Non-Malignant Disorders Treated With Cord Blood
Disorder Number Treated Outcome Ref.
Hurler's syndrome 20 17 of the 20 children were alive a median of 905 days after transplantation, with 
complete donor chimerism and normal peripheral-blood alpha-L-iduronidase 
activity
[100]
Duchenne muscular dystrophy 1 On 42nd day, physical examination revealed obviously improvement in walking, 
turning the body over, and standing up
[101]
Malignant infantile osteopetrosis 1 Normalization of spine bone mineral density. [102]
Rothmund-Thomson syndrome 1 Complete immune reconstitution [55]
Buerger's disease 4 Ischemic rest pain suddenly disappeared. Digital capillaries were increased in 
number and size.
[84]
Spinal Cord Injury 1 Improved sensory perception and movement in the SPI patient's hips and thighs 
within 41 days of cell transplantation. Regeneration of the spinal cord at the 
injured site
[85]
Krabbe's disease 25 Progressive central myelination and continued gains in developmental skills, and 
most had age-appropriate cognitive function and receptive language skills in 
patient subset
[14]
Omenn syndrome 1 T cell reconstitution [103]
Non-healing wounds 2 Accelerated healing [86]
Refractory anemia 3 All patients are alive and free of disease at between 17 and 39 months after 
cord blood administration
[104]
Diamond-Blackfan anemia 1 Successful seroconversion to vaccines (diphtheria, pertussis, tetanus, rubella, 
measles, and BCG) administered 22–34 months post-transplant.
[105]
Severe chronic active Epstein-Barr 
virus
1 Complete remission without circulating EBV-DNA has continued for 15 months 
transplant.
[106]
Behcet's disease 1 Twenty-three months after CBT, the patient is doing well and has no signs or 
symptoms of Behcet's disease
[9]
Mucopolysaccharidosis type IIB 
(Hunter syndrome)
1 Two years after transplant approximately 55% normal plasma iduronate 
sulfatase. activity has been restored and abnormal urinary excretion of 
glycosaminoglycans has nearly completely resolved.
[107]Journal of Translational Medicine 2007, 5:8 http://www.translational-medicine.com/content/5/1/8
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sources. Attesting to the robust hematopoietic activity of
cord blood derived CD34+ cells in comparison to bone
marrow cells is the fact that successful reconstitution,
albeit delayed, of post-ablative hematopoiesis occurs in
patients receiving approximately one tenth of the total
nucleated cell number in a cord blood graft compared to
a bone marrow graft.
Endothelial progenitors and angiogenesis stimulating cells
In addition to being a source of hematopoietic cells, cord
blood contains potent angiogenesis stimulating cells. Sev-
eral phenotypes have been ascribed to cord blood ang-
iogenic stimulating cells. In one report, the CD34+,
CD11b+ fraction, which is approximately less than half of
the CD34+ fraction of cord blood was demonstrated to
possess ability to differentiate into functional endothelial
cells in vitro and in vivo [19]. In another report, VEGF-
R3+, CD34+ cells were shown to possess not only the abil-
ity to differentiate into endothelial cells in vivo, but also
to be able to expand approximately 40-fold in vitro and
subsequently maintain angiogenic function in vivo. The
same study demonstrated that the concentration of this
endothelial progenitor fraction found in cord blood
CD34+ cells is approximately tenfold higher as compared
to bone marrow CD34+ cells [20]. Regardless of the phe-
notype of the cord blood cell with angiogenesis stimulat-
ing ability, unfractionated cord blood mononuclear cells
have also been used in numerous animal models [21-23],
as well as in the clinic [9], for successful stimulation of
angiogenesis.
In addition to endothelial progenitors, mesenchymal
stem cells (discussed below in more detail), which are
found in cord blood, are known to secrete numerous
cytokines and growth factors such as VEGF and FGF-2
[24,25] which stimulate angiogenic processes. In fact,
there are reports of mesenchymal stem cells contributing
to angiogenesis through direct differentiation into
endothelial cells [26].
Mesenchymal stem cells
Mesenchymal stem cells are a type of cell capable of differ-
entiating into various non-hematopoietic tissues. Cur-
rently this cell population is second to bone marrow stem
cells in terms of clinical entry in that Phase III clinical tri-
als are already underway with these cells. Mesenchymal
stem cells are classically defined as adhere to plastic and
expressing a non-hematopoietic cell surface phenotype,
consisting of CD34-, CD45-, HLA-DR-, while possessing
markers such as STRO-1, VCAM, CD13, CD29, CD44,
CD90, CD105, SH-3, and STRO-1 [27]. To date mesen-
chymal stem cells have been purified from bone marrow
[28], adipose tissue [29], placenta [30,31], scalp tissue
[32] and cord blood [33]. Cord blood-derived mesenchy-
mal stem cells have demonstrated ability to differentiate
into a wide variety of tissues in vitro including neuronal
[34-36], hepatic [37,38], osteoblastic [39], and cardiac
[33]. An important aspect of this cell population is their
anti-inflammatory and immunomodulator activity. For
example, they constitutively secrete immune inhibitory
cytokines such as IL-10 and TGF-β while maintaining abil-
ity to present antigens to T cells, thus suggesting they may
act as a tolerogenic antigen presenting cell [40,41]. Con-
ceptually, the mesenchymal content of umbilical cord
blood grafts may explain the tolerogenic capabilities,
which some have speculated to be donor specific.
Although the majority of published studies have exam-
ined bone marrow derived mesenchymal stem cells, and
thus are outside the scope of the present review, it is
important to note differences between mesenchymal stem
cells derived from different sources. A recent study com-
pared mesenchymal stem cells from bone marrow, cord
blood and adipose. Cord blood mesenchymal stem cells
which were capable of expansion to approximately 20
times, whereas adipose derived cells expanded an average
of 8 times and bone marrow derived cells expanded 5
times [42]. This, and other studies support the important
role of mesenchymal stem cell content in the biological
activities of the cord blood graft.
Unrestricted somatic stem cells
Cells with markers and activities resembling embryonic
stem cells have been found in cord blood. Zhao et al iden-
tified a population of CD34-  cells expressing OCT-4,
Nanog, SSEA-3 and SSEA-4, which could differentiate into
cells of the mesoderm, ectoderm and endoderm lineage.
In vivo administration of these cells into the streptozo-
tocin-induced murine model of diabetes was able to sig-
nificantly reduce hypoglycemia [43]. The existence of cells
with such pluripotency in cord blood was also observed
by Kogler et al who identified an Unrestricted Somatic
Stem Cell (USSC) with capability of differentiation into
functional osteoblasts, chondroblasts, adipocytes, hemat-
opoietic and neural cells. USSC were demonstrated to be
capable of > 40 population doublings in vitro without
spontaneous differentiation or loss of telomere length.
Interestingly, administration of these cells (derived from
human cord blood) into fetal sheep resulted significant
human hematopoiesis (up to 5%), hepatic chimerism
with > 20% albumin-producing human parenchymal
hepatic cells, as well as detection of human cardiomyo-
cytes. The mechanism of differentiation was not associ-
ated with fusion [44]. Support for presence of such
pluripotency in cord blood cells also comes from a similar
experiment in which CD34+ Lineage- cells were transfected
with GFP and administered in utero to goats. GFP+ cells
were detected in blood, bone marrow, spleen, liver, kid-
ney, muscle, lung, and heart of the recipient goats (1.2–
36% of all cells examined) [45]. In other studies,Journal of Translational Medicine 2007, 5:8 http://www.translational-medicine.com/content/5/1/8
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McGuckin et al demonstrated that culture of cord blood
cells that have been depleted of lineage committed cells in
a TPO, c-kit, and flt-3 ligand culture express markers of
embryonic stem cells including TRA-1–60, TRA-1–81,
SSEA-4, SSEA-3 and Oct-4. Functionally, these cells also
demonstrated pluripotent differentiation ability and in
vivo hematopoietic activity [46-48].
Cord blood transplantation without host 
preconditioning: will there be GVHD?
The possibility of using cord blood in absence of host pre-
conditioning would open up the door for a multitude of
stem cell therapeutic applications. The currently dogma
amongst cord blood transplanters is that administration
of allogeneic cord blood, even if HLA-matched, would in
the best case scenario lead to immunologically-mediated
rejection or the graft, and in the worst case cause GVHD.
Here we provide rationale for the preliminary clinical
exploration of cord blood administration in a non-pre-
conditioned host.
ABO-matched, HLA-mismatched transfusions
In the 1930s it was reported that cord blood could be
safely used as a substitute for peripheral blood for per-
forming transfusions [49]. Since HLA-matching was not
available at that time and no adverse effects were noted,
the feasibility of cord blood administration to a non-pre-
conditioned host was suggested. A more recent Lancet
publication described the use of cord blood as a source of
blood donation for malaria infested regions in Africa. 128
pediatric patients with severe anemia needing transfu-
sions were transplanted with an average of 85 ml of ABO
matched cord blood with no HLA matching. No report of
graft versus host was noted, and cord blood was proposed
as a transfusion source when peripheral blood is not avail-
able due to economical or social reasons [50]. An exten-
sive review of 129 patients transplanted with a total of 413
Units of cord blood (average 86 ml) with no precondi-
tioning or HLA matching between 1999 to 2004 was pub-
lished by Bhattacharya [51]. Of these patients, aged 2–86
years old and suffering from advanced cancer (56.58%)
and other diseases (43.42%) such as ankylosing spondyli-
tis, lupus erythematosus, rheumatoid arthritis, aplastic
anemia, and thalassemia major, no immunological reac-
tions were noted in patients followed for 1–4 years. The
same author reported other patient cohorts that have been
similarly treated and had no GVHD or other immune
reactions [52-55]. Furthermore, transfusion of cord blood
in non-HLA matched recipients was also associated with
transient increases in peripheral CD34 counts, without
evidence of GVHD in patients with cancer and HIV
[56,57]. Unfortunately in these studies did not perform
long-term molecular analysis for chimerism. Despite this
drawback, it is evident from the initial work in the 1930s,
to the numerous cases reported by Bhattacharya, to the
publication in Lancet, that administration of cord blood
is a safe procedure not associated with immunological
consequences. Thus based on the current data, the worse
a cord blood transplant will do is do nothing.
Administration of adult lymphocytes does not elicit GVHD
The cells that are "dangerous" from the cord blood from a
GVHD perspective are lymphocytes that may have allore-
active potential. Lymphocytes from cord blood, in con-
trast to adult blood, are generally immature and usually
do not secrete as many inflammatory cytokines. Therefore
administration of allogeneic lymphocytes purified from
adult blood would be a much more dangerous procedure,
at least as far as GVHD is concerned, in contrast to admin-
istration of lymphocytes from cord blood. The fact is
administration of lymphocytes from paternal sources has
been performed in numerous reports in the clinical prac-
tice of using "paternal lymphocyte immunotherapy" for
treatment of spontaneous abortions. Numerous trials
have been conducted administering doses of up to 2 × 109
paternal lymphocytes into pregnant mothers who have
had recurrent miscarriages [58,59]. These doses are higher
than the 1.5–3 × 107 nucleated cells/kg administered dur-
ing a cord blood transplant [60]. Interestingly, in preg-
nant women administered these high doses of completely
allogeneic cells, no GVHD has ever been observed,
although Th2 immune deviation has been reported by
some groups [61,62]. Thus according to the current evi-
dence, there is no fear of GVHD being induced after cord
blood transplant. Bhattacharya even administered as
many as 32 units of cord blood to an individual without
seeing GVHD [57].
Homeostatic proliferation in lymphopenic environment 
causes GVHD
The reader will ask, in response to the above arguments
regarding GVHD-inducing ability of cord blood, "why is
GVHD, a clinical reality in patients receiving cord blood for
hematological malignancies?" The answer is that current day
cord blood transplants take place following ablation of
host T cells. This creation of an "empty compartment"
allows for homeostatic expansion of the newly introduced
T cells, which primes them for aggressive immune reac-
tions and alleviates their requirement for costimulation
[63]. It is known from the transplantation literature that T
cells reconstituting a host that has been lymphoablated
are resistant to costimulatory blockade and tolerance
induction [64]. Furthermore, the pioneering experiments
of Rosenberg's group demonstrated that infusion of
tumor specific lymphocytes following ablation of the
recipient T cells, using conditions similar to those used in
cord blood transplant preconditioning allows for highly
aggressive anti-tumor responses that otherwise would not
be observed [65]. Further supporting the concept that
reconstitution of a lymphocyte deficient immune systemJournal of Translational Medicine 2007, 5:8 http://www.translational-medicine.com/content/5/1/8
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can cause immune hyperreactivity comes from clinical
observations of "autologous GVHD" in patients adminis-
tered drugs associated with induction of lymphopenia
[66,67]. We therefore propose that GVHD is not an intrin-
sic property of the allogeneic cells introduced into the
host, but a result of the lymphoablation induced in the
recipient prior to cellular administration.
Will the graft be cleared?
If cord blood can be administered into a non-precondi-
tioned patient without fear of GVHD, then the next ques-
tion arises as to whether the infused cells will actually
endow some type of benefit or be rapidly cleared by the
immune system. As previously mentioned, biological
effects of mismatched cells, even if they are cleared by the
immune system may have a beneficial role in inflamma-
tory pathologies through exertion of a Th2 phenotype as
seen in mothers being administered their mate's lym-
phocytes. Furthermore, even if transplanted cells are
cleared by the immune system, it is known that apoptotic
cells can mediate various therapeutic anti-inflammatory
effects that are clinically relevant [68]. Animal models
suggest that human cord blood cells may be administered
for therapeutic benefit into other species, in absence of
immune suppression. For example, Vendrame et al
reported that administration of human cord blood into a
non-immunosuppressed rat model of stroke resulted in
increased neuronal survival, and interestingly decreased
inflammatory infiltrates as compared to controls [69].
Fetal cells do not get cleared by maternal immune system
However, we do not believe that complete immune medi-
ated clearing of regeneratively-important cord blood con-
stituents occurs in the allogeneic setting. One reason for
this notion comes from an interesting phenomena
observed in pregnancy. It is well established that during
pregnancy fetal cells enter maternal circulation [70].
While circulating CD34+ cells of fetal origin are found a
percentage of women who have had children [71], in the
bone marrow 100% of women who have had children
were found to contain offspring-derived mesenchymal
cells in their bone marrow [72]. Although some studies
have correlated autoimmunity with residual lymphocytes
causing a GVHD-like reaction in the mother, more careful
analysis of these studies show that immune cells of fetal
origin are largely outnumbered by cells of maternal ori-
gin. This is the basis for the proposition of Khosrotehrani
et al that the fetal cells are actually "pregnancy associated
progenitor cells" that act as allogeneic "repair cells" [73].
The authors of this hypothesis believe that these repair
cells are actually migrating to the site of autoimmune
damage in order to control injury and cause regeneration.
The authors cite numerous examples in support of their
idea, more notably, a case report of a hepatitis C patient
who stopped treatment but disease relapse was not
observed. Biopsy analysis demonstrated the liver paren-
chyma was heavily populated with cells of male origin
that based on DNA polymorphism analysis were derived
from a previous pregnancy more than a decade earlier
[74]. Additionally, they cite reports of fetal cells differen-
tiating into thyroid, cervix, gallbladder and intestinal epi-
thelial cells [75-78]. Data from animal models, although
scarce, supports the notion that fetal cells trafficking into
the mother may play some reparative function. For exam-
ple, it was reported that EGFP expressing fetal cells would
selectively home into damaged maternal renal and
hepatic tissues after gentamycin and ethanol induced
injury [79]. Furthermore, another study demonstrated
that subsequent to excitotoxic injury in the maternal
brain, fetal-derived EFGP positive cells can be identified
which express morphology and markers of neurons, astro-
cytes, and oligodendrocytes [80]. The authors of this
paper are not stating that the fetal transfer of mesenchy-
mal cells to the maternal host is an exact duplicate of an
allogeneic cord blood transplant in absence of immune
suppression. Rather, we are proposing fetal to maternal
trafficking as a possible example of a natural biological sit-
uation in which stem cells may persist in an allogeneic
environment without induction of complete tolerance.
Mesenchymal stem cells do not need myeloablation for 
efficacy
Currently there are several ongoing clinical trials in Phase
I-III using "universal donor" mesenchymal stem cells in
non-conditioned recipients for treatment of Crohn's dis-
ease [81], GVHD [82], and myocardial infarction [83].
Although these cells are bone marrow expanded mesen-
chymal cells, the superior proliferative potential of cord
blood mesenchymal cells may allow them to not only
escape immune destruction, but also expand in vivo and
mediate therapeutic effects superior to those derived from
the bone marrow. The fact that regulatory agencies have
allowed advancement of "off-the-shelf" universal donor
mesenchymal stem cells supports the numerous reports of
clinical efficacy in an allogeneic setting.
Clinical evidence of cord blood efficacy in absence of 
myeloablation
To the knowledge of the authors, there have only been 3
published reports of non-conditioned recipients receiving
cord blood cells for regenerative purposes. The first report
is of 4 patients with Buerger's disease who were adminis-
tered 4/6 HLA matched allogeneic cord blood cells locally
in the area of limb ischemia. In all patients rest pain dis-
appeared and necrotic lesions healed approximately 4
weeks subsequent to cell administration. Significant angi-
ographically evidenced neoangiogenesis proximal to area
of administration was observed [84]. No graft versus host,
or inflammation was observed at the site of injection. The
second published report is of a matrix delivered allogeneicJournal of Translational Medicine 2007, 5:8 http://www.translational-medicine.com/content/5/1/8
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cord blood dose to a patient who suffered from spinal
cord injury. Improved sensory perception and movement
was observed, as well as CT and MRI observation of tissue
regeneration at site of injury was reported [85]. The third
report described 2 patients with non-healing wounds who
were treated with autologous fibrin glue containing
matched (2 mismatches allowed) allogeneic cord blood
isolated CD34+  cells. Significant wound healing was
observed with no indication of GVHD at 3 and 7 months
subsequent to treatment [86]. These reports give some
suggestion that administration of mismatched cord blood
stem cells may endow potentially therapeutic benefit
without rejection, at least immediate rejection, by the host
versus graft process. More importantly, these studies dem-
onstrate that allogeneic cord blood cells may be used clin-
ically without immune-mediated clearing before
therapeutic properties are exerted.
Strategies for clinical implementation
Given the unique regenerative capabilities of cord blood,
the easy accessibility of HLA matched donors, and relative
inexpensiveness as compared to other cellular therapies; it
is of great interest therapeutically to expand its use into
non-conditioned recipients. Below we will provide some
initial thoughts on how this may be performed.
Cord blood together with stem cell activators
One simple method of stem cell therapy would be admin-
istration of cord blood units in patients with degenerative
diseases in the form of direct transfusions has described
by Bhattacharya [57]. This approach, however has not
demonstrated significant regenerative activity. A more
promising approach may be administration of cord blood
cells in combination with activators of endogenous stem
cells. For example, clinically used agents such as thalido-
mide [87], valproic acid [88], or 5-azacytidine [89,90] all
have demonstrated ability to induce proliferation of
CD34+ stem cells in vitro and/or in vivo. In the majority
of cases, stem cell activating compounds are administered
for therapeutic benefit in absence of addition of exoge-
nous stem cell sources. One example is current clinical tri-
als of hCG and EPO for treatment of acute stroke [91]. The
addition of exogeneous allogeneic stem cells to clinically
accepted stem cell expanding agents may be a relatively
easy initial clinical trial of regenerative cord blood therapy
in absence of recipient conditioning. An interesting addi-
tion to administration of stem cell activators is the local-
ized introduction of stem cell specific chemoattractant
agents at the site in need of repair, followed by systemic
administration of cord blood stem cells. Chemoattractant
agents could include stromal derived growth factor-1 [92],
other various agonists of CXCR-4 [93], or hepatocyte
growth factor [94].
Cord blood plus natural chemoattractant
An alternative approach to administration of exogenous
stem cell chemoattractants would be to administer stem
cells at the narrow window period after tissue injury when
endogenous chemoattractants are secreted by the injured
tissue. For example, following myocardial infarction, as
well as stroke, there is a period of time which concentra-
tion of local stem cell chemoattractants are so high that
bone marrow derived progenitors are actually mobilized
into systemic circulation [95]. Activators of endogenous
stem cells may be administered to allow localized tissue
repair, while exogenous stem cells are administered to
provide support to the activated endogenous cells.
De-immunogenized cord blood graft
Clinical entry of a cord blood therapeutic in patients who
are not preconditioned would require a high margin of
safety to be met. Accordingly, one approach for beginning
cord blood clinical trials may be administration of grafts
that are depleted of T cells, B cells, and dendritic cells. In
this manner, even the remote possibility of GVHD would
be negated, and the there would be no B cell or dendritic
cell induced antigenicity. Essentially, the percentage stem
cell content of the graft would increase while the possible
immunogenic components would decrease. A method of
accomplishing this would be the pretreatment of cord
blood units with the clinically used anti-CD52 mono-
clonal antibody CAMPATH. It has been previously dem-
onstrated that this agent can be used in substantially
"cleaning" grafts of T cells without affecting hematopoi-
etic activity both in vitro [96] and in the clinic [97]. Fur-
thermore, CAMPATH has been shown to deplete B cells
[97], as well as circulating blood dendritic cells [98,99].
An ideal indication for utilization of such a treatment
would be in limb ischemia in which a variety of stem cell
sources have demonstrated angiogenic effects, however
clinical implementation of stem cells for limb ischemia is
currently limited by the difficulties of obtaining and puri-
fying autologous stem cells.
Conclusion
In summary, the authors propose that expanding the use
of cord blood to non-preconditioned adult recipients for
regenerative purposes would be a great step for the practi-
cal advancement of stem cell therapeutics. By overcoming
allogeneic barriers in regenerative medicine, the funda-
mental limitations of autologous cell therapy may result
in effective standardized "off-the-shelf" cellular products
for regenerative therapeutics. This major step can only be
performed by understanding the unique immunology of
cord blood grafts, leveraging the graft's regenerative capa-
bility for specific indications, and identifying methods of
amplifying cellular effects through administration of vari-
ous drugs.Journal of Translational Medicine 2007, 5:8 http://www.translational-medicine.com/content/5/1/8
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